Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Antoni Ribas

Has grant

Professor

University of California, Los Angeles

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Recent Grants

Grant: Close

Advancing T cell Therapy for Uveal Melanoma with Dual Antigen Targeting

Open Date: 2024-07-01

Close Date: 2026-06-30

Grant: Close

Combination Therapies to Defeat Melanoma Resistance

Open Date: 2020-09-11

Close Date: 2025-06-30

Grant: Close

IL13Ra2 Chimeric Antigen Receptor (CAR) T cells for Metastatic Melanoma

Open Date: 2020-08-01

Close Date: 2024-07-31

Grant: Close

Evaluating myeloid cells as targets to promote anti-tumor immunity in undifferentiated pleomorphic sarcoma

Open Date: 2018-06-01

Close Date: 2019-05-31

Grant: Close

Reversing primary anti-PD-1 resistance with ipilimumab and nivolumab

Open Date: 2017-05-01

Close Date: 2022-10-31

Articles (16)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Collaborators (14)

Kristin G Anderson

Assistant Professor

University of Virginia

UNITED STATES

View details

Anusha Kalbasi

Associate Professor

Stanford University

UNITED STATES

View details

Stephanie Dougan

Associate Professor

Dana-Farber Cancer Institute

UNITED STATES

View details

Gregory Daniels

University of California, San Diego

UNITED STATES

View details

E John Wherry

Professor

University of Pennsylvania

UNITED STATES

View details

Mohammed Milhem

Oncology Section Chief

University of Iowa Healthcare

UNITED STATES

View details

Catherine Blish

Association Professor

Stanford University School of Medicine

UNITED STATES

View details

Cristina Puig Saus

Associate Professor

David Geffen School of Medicine at UCLA

UNITED STATES

View details

Megan Othus

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Haining Yang

Professor

University of Hawai'i Cancer Center

UNITED STATES

View details

Stefani Spranger

Massachusetts Institute of Technology

UNITED STATES

View details

Diwakar Davar

Associate Professor of Medicine; Clinical Director, Melanoma and Skin Cancer Program; Associate Chief, Academic Affairs

UPMC Hillman Cancer Center

UNITED STATES

View details

Mamatha Serasanambati

Senior Research Scientist

Stanford University

UNITED STATES

View details

David H Raulet

Professor

University of California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antoni Ribas

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (16)

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors

Design considerations for randomized comparisons of neoadjuvant–adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials

Basic rules to respond to PD-1 blockade cancer immunotherapy

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.

Antitumor Immune Responses in <i>B2M</i>-Deficient Cancers

Collaborators (14)

Kristin G Anderson

Anusha Kalbasi

Stephanie Dougan

Gregory Daniels

E John Wherry

Mohammed Milhem

Catherine Blish

Cristina Puig Saus

Megan Othus

Haining Yang

Stefani Spranger

Diwakar Davar

Mamatha Serasanambati

David H Raulet

Make your next move.